Cell Therapy Industry Overview
|Study Period:||2018 - 2028|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and its growth?
Cell Therapy Market Analysis
The cell therapy market is expected to witness a CAGR of 17.05% over the forecast period.
The impact of the COVID-19 pandemic on the cell therapy market is expected to be significant as most companies have been focusing on the development of cell-based therapies for COVID-19 treatment. For instance, in April 2020, Calidi Biotherapeutics Inc. revealed that the Investigational New Drug (IND) application submitted by its partner, Personalized Stem Cells Inc. (PSC), received the Food and Drug Administration approval for the treatment of COVID-19 and pneumonia patients using stem cell therapy. The impact of COVID-19 is also expected to have a positive impact on the studied market as most pharmaceutical, biotechnology, and research institutes have been focusing on the development of cell therapy-based treatment against COVID-19. For instance, according to the study published in Stem Cell Research & Therapy volume on ‘When stem cells meet COVID-19: recent advances, challenges and future perspectives’ published in January 2022, stem cell therapy and stem cell-derived organoid models have got a lot of attention as a new treatment and research method for COVID-19, and stem cells play a role in the battle against COVID-19. This will open up further opportunities for the market players to launch new products, which is expected to drive the market growth during the forecast period.
The cell therapy market is anticipated to witness healthy growth due to the increasing prevalence of chronic conditions, rising adoption of regenerative medicine, and rise in the number of clinical studies about the development of cellular therapies.
Chronic diseases and conditions are on the rise worldwide. As per the International Diabetes Federation Diabetes Altas, in 2021, nearly 573 million adults globally were living with diabetes worldwide, and the number is expected to reach 643 million by 2030 and 783 million by 2045.
Therefore, the increasing prevalence of chronic conditions, government assistance, and numerous companies investing heavily in stem cell therapy research and development are predicted to stimulate industry growth. The proven effectiveness of cell therapy products, coupled with the increasingly favorable guidelines on cell therapy research and manufacturing, is likely to positively impact the market growth over the forecast period. On the other hand, the high cost associated with cell therapies is expected to hinder market growth.
Cell Therapy Industry Segments
As per the scope of the report, cell therapy is known as a type of therapy in which live cells are injected into a patient for the treatment of a number of disorders by replacing diseased or dysfunctional cells with healthy functioning ones. Some of the cells used for the treatment include hematopoietic (blood-forming) stem cells (HSC), skeletal muscle stem cells, mesenchymal stem cells, lymphocytes, dendritic cells, and pancreatic islet cells, among others. The cell therapy market is segmented by type (autologous and allogeneic), therapy (mesenchymal stem cell therapy, fibroblast cell therapy, hematopoietic stem cell therapy, and other therapies), application (musculoskeletal, malignancies, cardiovascular, dermatology and wounds, and other applications) and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for all the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across the major regions globally.
|Mesenchymal Stem Cell Therapy|
|Fibroblast Cell Therapy|
|Hematopoietic Stem Cell Therapy|
|Dermatology and Wounds|
Cell Therapy Market Trends
This section covers the major market trends shaping the Cell Therapy Market according to our research experts:
The Allogeneic Therapies Segment is Expected to Account for a Significant Share in the Cell Therapy Market
Allogeneic therapies rely on a single source of cells to treat many patients. They increase the risk of eliciting an immune response within a patient, and immunosuppressive therapies are sometimes administered in combination with allogeneic products. Therefore, the increasing inclination of physicians toward the therapeutic use of allogeneic therapies and rising awareness about the use of cord cells and tissues across various therapeutic areas are some of the major factors driving the growth. Allogenic cells have benefits as they produce their own immune stem cells that kill the cancer cells that remain even after high-dose treatment with cytotoxic drugs. This response is called a graft-versus-cancer effect, and this is used in the prevention or treatment of cancer relapse. The aforementioned factors are expected to drive the market over the forecast period.
The rising number of clinical trials required to gain regulatory approval for new medications to advance patient care is expected to boost the segment growth. For instance, ALLO-501, ALLO-501A, ALLO-715, UCART19, and UCART19 by Allogene provide growth opportunities for the segmental growth.
Moreover, in January 2020, Allogene Therapeutics Inc. and SpringWorks Therapeutics Inc. entered a clinical trial collaboration agreement for the evaluation of ALLO-715, along with Nirogacestat, in multiple myeloma patients.
Thus, owing to the rising number of research studies on allogenic therapy for cancer and associated benefits, the studied segment is anticipated to register steady growth over the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Dominate the Market Over the Forecast Period
North America is estimated to retain the largest share of the cell therapy market due to the presence of a strong regulatory framework to promote cellular therapy development, the existence of industry key players, and the presence of leading universities that support the research activities in the United States. Factors attributing to the high growth of the market in the region include the increasing prevalence of chronic conditions, rising adoption of regenerative medicine, and rise in the number of clinical studies about the development of cellular therapies.
Rising investments from market players for the development and expansion of cell-based therapies in the United States are expected to drive the market in North America. For instance, in January 2022, Cellino Biotech, an autonomous cell therapy manufacturing company, raised USD 80 million Series A financing round. Cellino plans to expand access to stem cell-based therapies with the intention to build the first autonomous human cell foundry in 2025. The applications of stem cell technologies in the treatment of diseases have ultimately increased the overall adoption rate of these technologies across the world. This has led to increased investments by market players in the development of novel therapies in this area.
Furthermore, improved results of cell therapy products for the treatment of cancers will lead to a rise in product development, which is expected to drive the growth of this market. For instance, in June 2021, Gilead’s Yescarta CAR T-cell therapy improved event-free survival by 60% in second-line relapsed or refractory large B-cell lymphoma patients. In addition, in June 2021, Bristol-Myers Squibb reported positive topline results from the phase 3 TRANSFORM Trial evaluating Breyanzi (lisocabtagene maraleucel) in second-line relapsed or refractory large B-cell lymphoma.
Therefore, rising investments and research initiatives by the key market players and positive results of cell therapies are the factors expected to drive the growth of this market in North America.
To understand geography trends, Download Sample Report
Cell Therapy Market Competitor Analysis
The cell therapy market is moderately competitive, with the presence of a considerable number of companies. The major companies in this market are evolving through various strategies such as investment in research and development, acquisitions, partnerships, and collaborations to secure their market positions. The major companies of the studied market are Pharmicell Co. Ltd, Corestem Inc., Chiesi Farmaceutici SpA, Tegoscience, Anterogen Co. Ltd, and TiGenix (Takeda Pharmaceuticals), among others.
Cell Therapy Market Top Players
PHARMICELL Co., Ltd
Chiesi Farmaceutici S.p.A.
Anterogen Co., Ltd.
*Disclaimer: Major Players sorted in no particular order
Cell Therapy Market Recent Developments
- In January 2022, Immunocore received the Food and Drug Administration approval of KIMMTRAK (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma.
- In March 2021, Novadip Biosciences received Investigational New Drug (IND) approval from the Food and Drug Administration for regenerative bone product NVD-003 for the treatment of rare pediatric bone disease.
Cell Therapy Market Report - Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Conditions
4.2.2 Rising Adoption of Regenerative Medicine
4.2.3 Rise in Number of Clinical Studies Pertaining to the Development of Cellular Therapies
4.3 Market Restraints
4.3.1 High Cost of Therapies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value – USD million)
5.2.1 Mesenchymal Stem Cell Therapy
5.2.2 Fibroblast Cell Therapy
5.2.3 Hematopoietic Stem Cell Therapy
5.2.4 Other Therapies
5.3.4 Dermatology and Wounds
5.3.5 Other Applications
5.4.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle-East and Africa
5.4.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Anterogen Co. Ltd
6.1.2 Tego Science
6.1.3 Chiesi Farmaceutici SpA
6.1.4 Corestem Inc.
6.1.5 Pharmicell Co. Ltd
6.1.6 Fibrocell Technologies Inc.
6.1.7 Nipro Corporation
6.1.8 MEDIPOST Co. Ltd
6.1.9 TiGenix (Takeda Pharmaceuticals)
6.1.10 Stempeutics Research Pvt. Ltd
6.1.11 Gilead Sciences Inc. (Kite Pharma Inc.)
6.1.12 Allogene Therapeutics Inc.
6.1.13 Novartis AG
6.1.14 Vericel Corporation
6.1.15 Organogenesis Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Cell Therapy Market Research FAQs
What is the study period of this market?
The Cell Therapy Market is studied from 2018 - 2028.
What is the growth rate of Cell Therapy Market?
The Cell Therapy Market is growing at a CAGR of 17.05% over the next 5 years.
Which region has highest growth rate in Cell Therapy Market?
Asia Pacific is growing at the highest CAGR over 2018 - 2028.
Which region has largest share in Cell Therapy Market?
North America holds highest share in 2021.
Who are the key players in Cell Therapy Market?
PHARMICELL Co., Ltd , Corestem Inc., Chiesi Farmaceutici S.p.A., Tego Science, Anterogen Co., Ltd. are the major companies operating in Cell Therapy Market.
Cell Therapy Industry Reports
In-depth industry statistics and market share insights of the Cell Therapy sector for 2020, 2021, and 2022. The Cell Therapy research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to 2028. Available to download is a free sample file of the Cell Therapy report PDF.